Filtered By:
Education: Learning
Management: Centers for Disease Control and Prevention (CDC)
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 42 results found since Jan 2013.
How People With Diabetes Can Lower Stroke Risk
After spending nearly two decades trying to manage her Type 2 diabetes, Agnes Czuchlewski landed in the emergency room in 2015, with news that she’d just experienced a heart attack. She also learned that she had metabolic syndrome, a cluster of conditions that includes diabetes but also brings higher risk of heart disease and stroke.
“Because I needed to lose quite a bit of weight when I was first diagnosed, I was focused on the number I saw on the scale, and then on my blood-sugar numbers,” recalls Czuchlewski, 68, who lives in New York City. “I didn’t realize other numbers came into play, li...
Source: TIME: Health - November 10, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease healthscienceclimate Source Type: news
Know the signs of heat stroke and exhaustion
Heat can be deadly.As summer temperatures climb — and as climate change contributes to more 100-degree days each year — heat illnesses become a more serious risk, particularly for young children, older adults, outdoor workers, athletes and people with chronic conditions.“On any day with extreme heat, emergency rooms in Los Angeles see an additional 1,500 patients,” said Dr. David Eisenman, a professor at the UCLA Fielding School of Public Health and co-leader of aresearch project to address extreme heat in Los Angeles.“We estimate that an additional 16 people die on a single day of heat in Los Angeles County,...
Source: UCLA Newsroom: Health Sciences - June 23, 2022 Category: Universities & Medical Training Source Type: news
Johnson & Johnson Launches Heartline ™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline™ Study. The study is designed to explore if the Heartline™ Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection of atrial fibrillation (AFib). AFib, a common form of irregular heart rhythm, is a leading cause of stroke in the U.S. To enroll in the Heartline™ Study, individuals must be age 65 or older...
Source: Johnson and Johnson - February 25, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Consumer Health: Recovering from a stroke
May is National Stroke Awareness Month, which makes this a good time to learn more about recovering from a stroke with stroke rehabilitation. Stroke is one of the leading causes of death in the U.S. and a major cause of serious disability for adults. More than 795,000 people in the U.S. have a stroke each year, according to the Centers for Disease Control and Prevention. Stroke risk increases with age, especially after 55, but strokes can occur at…
Source: News from Mayo Clinic - May 30, 2022 Category: Databases & Libraries Source Type: news
Consumer Health: Do you know the warning signs of stroke?
May is National Stroke Awareness Month, which makes this a good time to learn about the warning signs of stroke and the need for prompt treatment. Stroke is one of the leading causes of death in the U.S. and a major cause of serious disability for adults. More than 795,000 people in the U.S. have a stroke each year, according to the Centers for Disease Control and Prevention. Stroke risk increases with age, especially after 55, but strokes…
Source: News from Mayo Clinic - May 3, 2022 Category: Databases & Libraries Source Type: news
Consumer Health: Stroke -- know the signs and risk factors
May is National Stroke Awareness Month, which makes this a good time to learn more about the signs and risk factors for stroke. Stroke is one of the leading causes of death in the U.S. and a major cause of serious disability for adults. More than 795,000 people in the U.S. have a stroke each year, according to the Centers for Disease Control and Prevention. A stroke occurs when the blood supply to part of your brain is interrupted…
Source: News from Mayo Clinic - May 3, 2023 Category: Databases & Libraries Source Type: news
How to Protect Outdoor Workers (and yourself) from Heat Stroke
In a typical year 658 Americans die from heat-related causes, according to the U.S. Centers for Disease Control and Prevention. This summer extreme heat in the Southwest has left one man dead from heat stroke and dozens of people hospitalized due to heat-related illnesses . Researchers at Columbia University predict an increase in the number of heat waves over the next few years, suggesting a growing need for those who work or play outside to learn how to recognize and avoid heat-related illnesses. [More]
Source: Scientific American - Official RSS Feed - July 8, 2013 Category: Science Tags: Health,Everyday Science,Climate,Health Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Between Extremes: Health Effects of Heat and Cold
Nate Seltenrich covers science and the environment from Petaluma, CA. His work has appeared in High Country News, Sierra, Yale Environment 360, Earth Island Journal, and other regional and national publications.
Background image: © Roy Scott
About This Article open
Citation: Seltenrich N. 2015. Between extremes: health effects of heat and cold. Environ Health Perspect 123:A275–A279; http://dx.doi.org/10.1289/ehp.123-A275
Published: 1 November 2015
PDF Version (2.4 MB)
Although heat waves and cold snaps pose major health risks and grab headlines when they occur, recent studies have uncovered a more complex and...
Source: EHP Research - November 2, 2015 Category: Environmental Health Authors: Web Admin Tags: Featured Focus News November 2015 Source Type: research
Is FDA Getting More Cozy with AI?
The use of artificial intelligence (AI) is undoubtedly on the rise in healthcare. From fledging medtech companies to established giants like Watson IBM—many firms are riding the current AI wave. Not only are companies embracing technology, but so is FDA.
Recently the agency gave approval to San Francisco-based Viz.ai’s Contact application, a type of clinical decision support software designed to analyze CT results that could notify providers of a potential stroke in their patients. “What it’s doing is comparing the imaging features in that patient with the millions of images it has been trained on in the past, in...
Source: MDDI - February 14, 2018 Category: Medical Devices Authors: Omar Ford Tags: Medical Device Business Digital Health Source Type: news
What to Know if Your Doctor Put You on Statins to Lower Cholesterol
High cholesterol is a prime example of having too much of a good thing. Our bodies naturally make this substance in the liver and then transport it throughout the body for multiple functions, including hormone regulation, cell tissue regeneration, and vitamin absorption. When the system is working well, cholesterol can boost overall health. But when a certain type called low-density lipoprotein—LDL, sometimes dubbed the “bad” kind—is overproduced, not only does it block the “good” kind called high-density lipoprotein (HDL), but it can also begin to accumulate in the arteries and form thi...
Source: TIME: Health - January 25, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
